"Shares of Pfizer (NYSE: PFE) gained 3.69% over the past month after gaining 9.90% the month prior. The stock's year-to-date loss now stands at 3.91%. Over the past year, PFE is up just 0.04%. A recent rally in Big Pharma stocks can be partially attributed to the Trump administration announcing a plan for TrumpRx, which seeks to lower prescription costs for Americans, with Pfizer working in partnership with the federal government."
"Pfizer continues to search for its footing in 2025 despite strong year-end 2024 results driven by stronger-than-expected sales from its COVID products, as well as its non-COVID products, such as Vyndaquel, Padcev and Eliquis. The 176-year-old Big Pharma mainstay has been at the forefront of its industry for several decades. Long known for its mass production of santonin (an antiparasitic drug), penicillin, and antibiotics, the latter part of the 20th century saw Pfizer invent Viagra (erectile dysfunction), Zoloft (anti-depressant) and Lipitor (high cholesterol) treatments,"
Pfizer reported Q3 EPS of $0.87 and revenue of $16.65 billion, beating expectations. Shares rose 3.69% over the past month following a 9.90% gain the month prior, leaving a year-to-date loss of 3.91% and a one-year change near flat. The company is part of a TrumpRx initiative aimed at lowering U.S. prescription costs through federal partnership. Strong late-2024 sales from COVID and non-COVID products supported recent results. Long-term performance shows a 36.61% decline over five years and a more than 56% drop since the December 2021 high. Dividend payouts totaled $9.5 billion in 2024, yielding 6.73%.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]